AcelRx Pharmaceuticals plans to file marketing approval for its drug-device combination for post-operative pain, which was found to be as effective as standard care, according to CNBC.
The company plans to file in the third quarter of 2013. AcelRx tested its ARX-01 Sufentanil NanoTab patient-controlled analgesia system against intravenous PCA with morphine on 359 adult patients. Initial data shows the NanoTab to be significantly better than intravenous morphine.
While intravenous morphine PCAs are common in hospitals, morphine can cause nausea, vomiting and other opioid-related side effects. It also carries a higher risk of addiction. Rather than morphine, the NanoTab administers sufentanil, another opioid with fewer side effects.
More Articles on Anesthesia:
4 Capabilities of ACO-Ready Anesthesia Groups
Anesthesia Business Consultants to Resell EHR as F1RSTUse
Decision Tree-Based Learning Improves Anesthesia Consumption Predictions
The company plans to file in the third quarter of 2013. AcelRx tested its ARX-01 Sufentanil NanoTab patient-controlled analgesia system against intravenous PCA with morphine on 359 adult patients. Initial data shows the NanoTab to be significantly better than intravenous morphine.
While intravenous morphine PCAs are common in hospitals, morphine can cause nausea, vomiting and other opioid-related side effects. It also carries a higher risk of addiction. Rather than morphine, the NanoTab administers sufentanil, another opioid with fewer side effects.
More Articles on Anesthesia:
4 Capabilities of ACO-Ready Anesthesia Groups
Anesthesia Business Consultants to Resell EHR as F1RSTUse
Decision Tree-Based Learning Improves Anesthesia Consumption Predictions